Clinical Manual for Management of the HIV-Infected ... - myCME.com
Clinical Manual for Management of the HIV-Infected ... - myCME.com
Clinical Manual for Management of the HIV-Infected ... - myCME.com
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Primary <strong>HIV</strong> Infection<br />
Background<br />
Primary <strong>HIV</strong> infection refers to <strong>the</strong> very early stages<br />
<strong>of</strong> <strong>HIV</strong> infection, or <strong>the</strong> interval from initial infection<br />
to <strong>the</strong> time that antibody to <strong>HIV</strong> is detectable. During<br />
this stage <strong>of</strong> <strong>HIV</strong> infection, patients typically have<br />
symptoms <strong>of</strong> acute <strong>HIV</strong> seroconversion illness, very<br />
high <strong>HIV</strong> RNA levels <strong>of</strong> >100,000 copies/mL, and<br />
negative or indeterminate <strong>HIV</strong> antibody tests.<br />
The diagnosis <strong>of</strong> patients with primary <strong>HIV</strong> infection<br />
is a clinical challenge. The symptoms <strong>of</strong> primary <strong>HIV</strong><br />
are nonspecific, and although many patients seek<br />
medical care <strong>for</strong> symptoms <strong>of</strong> <strong>HIV</strong> seroconversion<br />
illness, <strong>the</strong> diagnosis <strong>com</strong>monly is missed at initial<br />
presentation. The difficulties involve recognizing<br />
<strong>the</strong> clinical presentation <strong>of</strong> acute <strong>HIV</strong> infection and<br />
testing patients appropriately. In <strong>HIV</strong> treatment<br />
clinics, clinicians generally do not see patients with<br />
primary <strong>HIV</strong> infection, unless <strong>the</strong>y are referred with<br />
this diagnosis already established. In o<strong>the</strong>r health care<br />
settings, clinicians may not be familiar with <strong>the</strong> signs<br />
and symptoms <strong>of</strong> acute <strong>HIV</strong> infection and <strong>of</strong>ten do not<br />
consider this diagnosis.<br />
After infection with <strong>HIV</strong>, it takes a median <strong>of</strong> 25<br />
days be<strong>for</strong>e <strong>the</strong> <strong>HIV</strong> antibody test be<strong>com</strong>es positive;<br />
in some individuals, it may be several months be<strong>for</strong>e<br />
seroconversion. Individuals with known exposures to<br />
<strong>HIV</strong>, whe<strong>the</strong>r occupational or not, should be monitored<br />
closely beginning at about 3 weeks after exposure<br />
(routine monitoring at 6 weeks, 3 months, and 6<br />
months after exposure to <strong>HIV</strong> is likely to result in<br />
delayed diagnosis <strong>of</strong> <strong>HIV</strong> infection). For in<strong>for</strong>mation on<br />
postexposure prophylaxis, see chapters Nonoccupational<br />
Postexposure Prophylaxis and Occupational Postexposure<br />
Prophylaxis.<br />
S: Subjective<br />
More than three quarters <strong>of</strong> patients who be<strong>com</strong>e<br />
infected with <strong>HIV</strong> develop symptoms consistent with<br />
primary <strong>HIV</strong> infection. Symptoms typically appear<br />
a few days to a few weeks after exposure to <strong>HIV</strong>, and<br />
generally include several <strong>of</strong> <strong>the</strong> following:<br />
♦<br />
♦<br />
♦<br />
Fever<br />
Rash, <strong>of</strong>ten ery<strong>the</strong>matous maculopapular<br />
Fatigue<br />
Section 1—Testing and Assessment | 1–33<br />
♦ Pharyngitis<br />
♦ Generalized lymphadenopathy<br />
♦ Urticaria<br />
♦ Myalgia/arthralgia<br />
♦ Anorexia<br />
♦ Mucocutaneous ulceration<br />
♦ Headache, retroorbital pain<br />
♦<br />
Neurologic symptoms (eg, aseptic meningitis,<br />
radiculitis, myelitis)<br />
This symptomatic phase usually persists <strong>for</strong> 2-4 weeks<br />
or less, although lymphadenopathy may last longer.<br />
These symptoms and signs are similar to those <strong>of</strong> many<br />
o<strong>the</strong>r illnesses, including o<strong>the</strong>r viral syndromes. To<br />
diagnose early <strong>HIV</strong> infection, clinicians must consider<br />
<strong>HIV</strong> in <strong>the</strong> differential diagnosis <strong>for</strong> at-risk patients<br />
with symptoms resembling flu or mononucleosis. A<br />
history <strong>of</strong> recent risk behaviors should be obtained from<br />
all patients who present with symptoms consistent with<br />
acute <strong>HIV</strong> infection.<br />
O: Objective<br />
During <strong>the</strong> symptomatic phase <strong>of</strong> <strong>HIV</strong> seroconversion,<br />
<strong>the</strong> <strong>HIV</strong> antibody test is likely to be negative or<br />
indeterminate. For patients who have symptoms<br />
consistent with seroconversion illness and a recent<br />
high-risk history <strong>for</strong> <strong>HIV</strong> exposure, an <strong>HIV</strong> RNA<br />
(viral load) test should be per<strong>for</strong>med, in addition to <strong>the</strong><br />
<strong>HIV</strong> antibody test, as part <strong>of</strong> <strong>the</strong> evaluation. Patients<br />
with negative antibody tests but high <strong>HIV</strong> viral loads<br />
(>100,000 copies/mL) can be considered to be infected<br />
with <strong>HIV</strong>, although <strong>the</strong> antibody test should be<br />
repeated later to confirm seroconversion. False-positive<br />
<strong>HIV</strong> viral loads have been reported in approximately 5%<br />
<strong>of</strong> patients who were tested after <strong>HIV</strong> exposures. A low<br />
viral load (100,000 copies/mL and <strong>of</strong>ten<br />
millions <strong>of</strong> copies/mL) in acute infection. Patients who<br />
have indeterminate <strong>HIV</strong> antibody test results, low <strong>HIV</strong><br />
viral loads, and no clear <strong>HIV</strong> risk factors or symptoms<br />
<strong>of</strong> primary <strong>HIV</strong> infection should have repeat antibody<br />
testing in 4-6 weeks, without o<strong>the</strong>r interventions. For<br />
patients without significant risk factors, indeterminate<br />
results rarely indicate evolving seroconversion.